Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Palisade Bio (PALI) Shares Outstanding (Diluted Average) (2016 - 2025)

Palisade Bio (PALI) has disclosed Shares Outstanding (Diluted Average) for 6 consecutive years, with $5.7 million as the latest value for Q3 2025.

  • On a quarterly basis, Shares Outstanding (Diluted Average) rose 388.07% to $5.7 million in Q3 2025 year-over-year; TTM through Sep 2025 was $5.7 million, a 388.07% increase, with the full-year FY2024 number at $1.4 million, up 210.62% from a year prior.
  • Shares Outstanding (Diluted Average) was $5.7 million for Q3 2025 at Palisade Bio, up from $4.8 million in the prior quarter.
  • In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $8.0 million in Q3 2021 to a low of $287702.0 in Q1 2023.
  • A 5-year average of $2.0 million and a median of $927254.0 in 2022 define the central range for Shares Outstanding (Diluted Average).
  • Peak YoY movement for Shares Outstanding (Diluted Average): tumbled 87.75% in 2022, then surged 524.32% in 2025.
  • Palisade Bio's Shares Outstanding (Diluted Average) stood at $8.0 million in 2021, then crashed by 88.93% to $880311.0 in 2022, then tumbled by 48.2% to $456014.0 in 2023, then skyrocketed by 210.62% to $1.4 million in 2024, then soared by 302.55% to $5.7 million in 2025.
  • Per Business Quant, the three most recent readings for PALI's Shares Outstanding (Diluted Average) are $5.7 million (Q3 2025), $4.8 million (Q2 2025), and $4.8 million (Q1 2025).